Cargando…

Psychofarmacological approach for Binge- eating disorders

INTRODUCTION: Binge-eating disorder (BED), is one of the most common eating disorder. Treatment aims to reduce binge-eating frequency and disordered eating–related cognitions, improve metabolic health and weight, and regulate mood (in patients with coexisting depression or anxiety) OBJECTIVES: The a...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz Martinez, V., Beato-Fernández, L., Segura-Escobar, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565754/
http://dx.doi.org/10.1192/j.eurpsy.2022.596
_version_ 1784808968092123136
author Muñoz Martinez, V.
Beato-Fernández, L.
Segura-Escobar, E.
author_facet Muñoz Martinez, V.
Beato-Fernández, L.
Segura-Escobar, E.
author_sort Muñoz Martinez, V.
collection PubMed
description INTRODUCTION: Binge-eating disorder (BED), is one of the most common eating disorder. Treatment aims to reduce binge-eating frequency and disordered eating–related cognitions, improve metabolic health and weight, and regulate mood (in patients with coexisting depression or anxiety) OBJECTIVES: The aim of this study was to examine the efficacy of lisdexamfetamine dimesylate in a simple of 50 women with a binge eating disorder diagnosis compare with selective serotonin reuptake inhibitor METHODS: Two groups were made, one with lisdexamfetamine and the other with selective serotonin reuptake inhibitor (fluoxetine). 20 women were in each group (total n=40). The doses depend of the binge symptoms and rates were from 30 to 70md/day for lisdexamfetamine and for fluoxetine the doses were from 20 to 60mg/day. RESULTS: Binge behaviors decreased with a 50mg/day dose of lisdexamfetamine. The 70mg/day doses present also less binge behaviors but also more adverse events. The 30mg/day doses did not decrease binge-eating behaviors. CONCLUSIONS: Lisdexamfetamine is the first pharmacological agent to receive FDA approval for use in adults with moderate to severe binge eating disorder. This study supports further assessment of lisdexamfetamine as a treatment option for decreasing binge eating behavior and also symptoms associated such as anxiety and obsessive and compulsive features in adults.Increased efficacy with increasing dosages of lisdexamfetamine suggests a dose-response relationship until 50mg/day. Women with a dose of 50mg/day of lisdexamfetamine report less adverse event, more adherence to treatment and improve their eating behaviors. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9565754
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95657542022-10-17 Psychofarmacological approach for Binge- eating disorders Muñoz Martinez, V. Beato-Fernández, L. Segura-Escobar, E. Eur Psychiatry Abstract INTRODUCTION: Binge-eating disorder (BED), is one of the most common eating disorder. Treatment aims to reduce binge-eating frequency and disordered eating–related cognitions, improve metabolic health and weight, and regulate mood (in patients with coexisting depression or anxiety) OBJECTIVES: The aim of this study was to examine the efficacy of lisdexamfetamine dimesylate in a simple of 50 women with a binge eating disorder diagnosis compare with selective serotonin reuptake inhibitor METHODS: Two groups were made, one with lisdexamfetamine and the other with selective serotonin reuptake inhibitor (fluoxetine). 20 women were in each group (total n=40). The doses depend of the binge symptoms and rates were from 30 to 70md/day for lisdexamfetamine and for fluoxetine the doses were from 20 to 60mg/day. RESULTS: Binge behaviors decreased with a 50mg/day dose of lisdexamfetamine. The 70mg/day doses present also less binge behaviors but also more adverse events. The 30mg/day doses did not decrease binge-eating behaviors. CONCLUSIONS: Lisdexamfetamine is the first pharmacological agent to receive FDA approval for use in adults with moderate to severe binge eating disorder. This study supports further assessment of lisdexamfetamine as a treatment option for decreasing binge eating behavior and also symptoms associated such as anxiety and obsessive and compulsive features in adults.Increased efficacy with increasing dosages of lisdexamfetamine suggests a dose-response relationship until 50mg/day. Women with a dose of 50mg/day of lisdexamfetamine report less adverse event, more adherence to treatment and improve their eating behaviors. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9565754/ http://dx.doi.org/10.1192/j.eurpsy.2022.596 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Muñoz Martinez, V.
Beato-Fernández, L.
Segura-Escobar, E.
Psychofarmacological approach for Binge- eating disorders
title Psychofarmacological approach for Binge- eating disorders
title_full Psychofarmacological approach for Binge- eating disorders
title_fullStr Psychofarmacological approach for Binge- eating disorders
title_full_unstemmed Psychofarmacological approach for Binge- eating disorders
title_short Psychofarmacological approach for Binge- eating disorders
title_sort psychofarmacological approach for binge- eating disorders
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565754/
http://dx.doi.org/10.1192/j.eurpsy.2022.596
work_keys_str_mv AT munozmartinezv psychofarmacologicalapproachforbingeeatingdisorders
AT beatofernandezl psychofarmacologicalapproachforbingeeatingdisorders
AT seguraescobare psychofarmacologicalapproachforbingeeatingdisorders